Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of CZ10 in Healthy Volunteers
NCT06708767Phase 1Not yet recruiting
- Sponsor
- Nextrast Inc
- Start
- Jan 2050
- Primary completion
- Jan 2052
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of CZ10 in vascular disease (4 arms), sponsored by Nextrast Inc. Primary endpoints: Number of adverse events at 2 weeks, Abnormality cases in lab test results at 1 week and 3 more. Planned start Jan 2050; status: not yet recruiting.
02
Drugs
CZ10
03
Conditions
vascular disease
Beyond the preview
Go deeper on NCT06708767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708767.